RHO and cancer: Rho family proteins are important anti‐cancer drug targets, owing to their crucial roles in migration‐related signaling pathways, as well as their abnormal activation in various types of cancer.[7] Due to the sub‐nanomolar binding affinity of Rho GTPases for the substrates GDP and GTP, and the lack of any desirable binding sites in Rho GTPases, the Rho family GTPases are generally deemed “undruggable” for cancer treatment.